ESMO 2025 preview – Sanofi’s lead shot gets a boost
The group toplines a phase 2 win with Alphamedix.
GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
Boehringer goes earlier than Bayer
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
ESMO 2025 preview – Astra and Daiichi keep abreast of Gilead
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
A milestone for Tmalin
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
